NASDAQ$DYN
Dyne Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year 2023 and recent business highlights.
Dyne Therapeutics reported positive initial clinical data from ACHIEVE and DELIVER trials, demonstrating proof-of-concept for their FORCE™ platform. They strengthened their balance sheet with a $345 million public offering, extending their cash runway through 2025. The company is focused on optimizing dose and dose regimen in 2024 and plans to provide updates from both trials in the second half of the year.
- Reported positive initial clinical data from the ACHIEVE trial in DM1 patients.
- Reported positive initial clinical data from the DELIVER trial in DMD patients.
- Completed a $345 million public offering, extending projected cash runway through 2025.
- Plan to report data from multiple, higher dose cohorts from both the ACHIEVE and the DELIVER trials in the second half of 2024.
Headline financials
Revenue & EPS history
Dyne Therapeutics · Revenue · Quarterly
$3.79M
Forward guidance
Dyne anticipates reporting data from multiple, higher dose cohorts from both the ACHIEVE and the DELIVER trials in the second half of 2024 with the goal of initiating registrational cohorts by the end of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
+1.8%
Avg return
Earnings day
-2.5%
Avg return
5 days after
+3.0%
Avg return
30 days after
59%
13 / 22 earnings
Positive
+21.3%
Q3 2024
Best reaction
-6.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q4 2025 | +3.6% | -4.9% | +15.9% | |
| Q3 2025 | -2.8% | -14.0% | -5.8% | |
| Q2 2025 | -1.3% | +7.9% | +47.7% | |
| Q1 2025 | +1.1% | +3.6% | +30.1% | |
| Q4 2024 | -4.5% | -13.8% | -17.0% | |
| Q3 2024 | +21.3% | +0.9% | -9.0% | |
| Q2 2024 | +0.5% | +5.7% | -22.0% | |
| Q1 2024 | +1.0% | -0.7% | +23.4% | |
| Q4 2023 | -3.4% | -9.2% | -4.5% | |
| Q3 2023 | +6.5% | +24.3% | +66.0% | |
| Q2 2023 | -1.8% | -15.6% | +0.1% | |
| Q1 2023 | -4.0% | -4.6% | -7.4% | |
| Q4 2022 | +10.1% | +8.3% | -15.5% | |
| Q3 2022 | +1.6% | -4.9% | +15.8% | |
| Q2 2022 | +4.3% | +1.1% | +1.0% | |
| Q1 2022 | +10.5% | -16.4% | -45.0% | |
| Q4 2021 | -1.7% | -2.9% | +16.5% | |
| Q3 2021 | +2.0% | +0.7% | -10.4% | |
| Q2 2021 | +3.3% | -4.1% | -9.6% | |
| Q1 2021 | +5.1% | +0.2% | +1.9% | |
| Q4 2020 | -6.5% | -6.2% | -4.4% | |
| Q3 2020 | -5.0% | -9.6% | -1.5% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro